Mayo Clinic proposes microdosimetry-based proton dose prescription beyond fixed RBE 1.1

A microdosimetry-based proton prescription model produced target-averaged RBE values of 1.08–1.18 while revealing substantially higher biological effectiveness near distal beam edges.

KEY POINTS

  • This computational physics study from Mayo Clinic Florida introduced a clinical proton dose-prescription system based on the Mayo Clinic Florida microdosimetric kinetic model (MCF MKM). Unlike conventional proton prescription using a uniform RBE of 1.1, the proposed framework accounts for microscopic energy-deposition distributions from primary protons and secondary particles, incorporating dose, radiation quality and cellular radiosensitivity into biological dose calculations.
  • The proposed clinical dose was defined as absorbed dose × biological RBE × clinical scaling factor, with the scaling factor fixed at 1.1. Biological RBE was calculated relative to proton radiation quality at the center of a reference 2 Gy(RBE) spread-out Bragg peak (SOBP) rather than directly relative to conventional photons. This maintains agreement with the established proton prescription convention at the reference point while allowing spatial variations in estimated biological effectiveness.
  • Calculations used OpenTOPAS Monte Carlo simulations and the human salivary gland tumor cell line parameters incorporated into the MCF MKM. Investigators evaluated SOBPs with prescribed clinical doses of 1, 2 and 8 Gy(RBE), target depths of 50–110, 150–210 and 250–310 mm, and different target widths, comparing their predictions with fixed RBE 1.1 and the Beltran and McNamara variable-RBE models.
  • Across the investigated configurations, target-averaged clinical RBE ranged from 1.08 to 1.18. For the reference 2 Gy(RBE) SOBP covering 150–210 mm, mean RBE was 1.12 (range 1.05–1.35) with MCF MKM, compared with 1.23 (1.15–1.47) using Beltran and 1.10 (1.07–1.21) using McNamara. These differences show that biological-dose predictions remain substantially dependent on model selection even when the underlying absorbed-dose distribution is identical.
  • Fraction dose materially influenced predicted RBE near the distal beam edge. At a depth of 216–217 mm, MCF MKM-derived RBE was approximately 2.0, 1.9 and 1.5 for prescriptions of 1, 2 and 8 Gy(RBE), respectively. This dose dependence is relevant to hypofractionated proton treatments, although the distal-edge region has a rapidly declining absorbed dose and high local RBE should not be interpreted independently of dose magnitude.
  • Including secondary charged particles altered the characterization of radiation quality despite their relatively small contribution to absorbed dose. Within the SOBP, protons contributed approximately 98.3–99.6% of absorbed dose, but at the reference mid-SOBP depth, dose-averaged LET was approximately 2.6 keV/μm when considering protons alone versus 5.1 keV/μm when including all ion species. The model also predicted elevated biological effectiveness in the lateral penumbra, reaching approximately RBE 1.4, and much higher values beyond the distal edge where the physical dose was low.
  • The proposed system remains a computational prescription framework evaluated in simplified water-phantom geometries, rather than a clinical treatment-planning trial. RBE predictions depend on the biological reference, selected cell-line parameters and model assumptions; computational demands and the absence of validated biological OAR constraints or outcome-based verification remain important barriers to routine use. The findings do not establish that the new prescription system improves toxicity or tumor control compared with fixed RBE 1.1.

CLINICAL TAKEAWAY

A microdosimetry-based prescription framework offers a structured way to incorporate variable proton RBE while retaining continuity with conventional clinical dosing. Its particular value may lie in evaluating biological dose near distal edges and in normal tissues, but clinical implementation requires independent validation, computational integration and outcome-based biological constraints before replacing established fixed-RBE planning.

SOURCE

International Journal of Radiation Oncology, Biology, Physics

Browse more research Suggest a correction